XE heads into its September 3 earnings report with options traders leaning heavily bullish — an unusual posture for a pre-revenue nuclear developer with a complicated regulatory path ahead.
The bullish tilt in options is the standout signal heading into the print. The put/call ratio has collapsed to 0.48, more than two standard deviations below its 20-day average of 0.61 — the most call-heavy reading in recent months. That gap from the norm is striking: for most of August, the PCR hovered steadily in the 0.62–0.68 range. The shift lower accelerated sharply in the final days of the month, coinciding with a 7.1% single-day gain on August 31 that lifted the stock to $18.45, up 13% from a month ago. Options traders are not hedging into this print — they are chasing upside.
The analyst community is broadly constructive, though with wide dispersion on how far the story can run. Bulls focus on X-Energy's proprietary Xe-100 small modular reactor technology, its anchor partnerships with Dow, Amazon, and Centrica, and a growing backlog that gives revenue visibility few early-stage clean energy names can claim. Government grant support further cushions the balance sheet runway. Bears counter with a credible list of structural concerns: NRC construction permit risk, a skilled-labor shortage specific to nuclear builds, and deep dependence on federal funding that could shift with policy winds. Uranium supply chain concentration adds another layer of execution risk. Cantor Fitzgerald reiterated its Overweight rating at a $38 target on August 14, while UBS trimmed its target to $34 from $40 in July though kept its Buy rating — a pattern of staying positive while selectively marking down near-term expectations. The consensus mean target of $38 implies more than 100% upside from current levels, a gap that reflects how far the stock has re-rated downward from where analysts initially set expectations.
The ownership structure tells an important part of the story. Amazon holds 22.9% of shares as a Schedule 13G passive filer — its stake disclosed as recently as August 6. Founder Kamal Ghaffarian controls roughly 25% per his August 14 filing, and Ares Partners disclosed a 12.3% position on August 12. These concentrated, recently disclosed stakes mean a large portion of the float is in strategic or founder hands, which both reduces the tradeable supply and makes each earnings cycle a referendum on the company's execution credibility for a small but attentive investor base. ORTEX's own stock score paints a more cautious picture beneath the surface: the score has fallen to 28 from 41 a month ago, dragged by weak fundamentals and negative earnings yields — a reminder that the options enthusiasm is sentiment-driven rather than grounded in traditional financial metrics.
History provides one useful reference. The most recent prior print, on August 13, delivered a modest 3.1% gain on the day but a brutal 10.1% loss over the following five sessions. The June print was worse: an 18.5% single-day drop followed by a 28.7% decline over five days. The September 3 report tests whether a stock that has recovered 13% in a month — and attracted unusually aggressive call buying — can finally deliver a result that holds the post-announcement bid.
See the live data behind this article on ORTEX.
Open XE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
